StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.62+0.05 (+0.12%)

Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –

Teva Pharmaceutical Industries Beneficial Interest Collected in Exchange for by Quarter

Beneficial Interest Collected in Exchange for Securitized Trade Receivables ($M)

Teva Pharmaceutical Industries Beneficial Interest Collected in Exchange for: $327M in Q3 2026, up 19.3% from a year earlier.

Latest, Q3 2026
327
Period ended Sep 30, 2026
Change on a year earlier
+19.3%
274 in Q3 2025
History
35 quarters
Since Q1 2018
Sources
31
Documents cited below

Where the Q3 2026 figure comes from

“|| Beneficial interest collected in exchange for securitized account receivables | 327 | 274”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Reported in SEC Form 10-K / Form 10-Q / Form 8-K Earnings Releases.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBeneficial Interest Collected in Exchange for Securitized Trade Receivables ($M)Year on yearSource
Q3 2026Sep 30, 2026327+19.3%Form 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 2026311-7.4%Form 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 2026354+9.9%Form 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 2025282-17.1%Form 8-K Earnings Release (0001171843-26-000462) ↗
Q3 2025Sep 30, 2025274-19.2%Form 8-K Earnings Release (0001171843-25-007000) ↗
Q2 2025Jun 30, 2025336+6.0%Form 8-K Earnings Release (0001171843-25-004808) ↗
Q1 2025Mar 31, 2025322+9.2%Form 8-K Earnings Release (0001171843-25-002849) ↗
Q4 2024Dec 31, 2024340-19.2%Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2024Sep 30, 2024339-6.4%Form 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 2024317-14.6%Form 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2024Mar 31, 2024295-8.7%Form 8-K Earnings Release (0001193125-24-133759) ↗
Q4 2023Dec 31, 2023421+47.2%Form 8-K Earnings Release (0001157523-24-000137) ↗
Q3 2023Sep 30, 2023362+38.2%Form 8-K Earnings Release (0001157523-23-001677) ↗
Q2 2023Jun 30, 2023371+29.3%Form 8-K Earnings Release (0001157523-23-001212) ↗
Q1 2023Mar 31, 2023323+5.9%Form 8-K Earnings Release (0001157523-23-000797) ↗
Q4 2022Dec 31, 2022286-22.7%Form 8-K Earnings Release (0001157523-23-000205) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Beneficial Interest Collected in Exchange for ($M), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/fcf-sec-ar

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?